Lifeline Biotechnologies Stock Performance
| LLBO Stock | USD 0.0002 0.0001 100.00% |
Lifeline Biotechnologies holds a performance score of 14 on a scale of zero to a hundred. The company secures a Beta (Market Risk) of -29.87, which conveys a somewhat significant risk relative to the market. As returns on the market increase, returns on owning Lifeline Biotechnologies are expected to decrease by larger amounts. On the other hand, during market turmoil, Lifeline Biotechnologies is expected to outperform it. Use Lifeline Biotechnologies total risk alpha and the relationship between the potential upside and price action indicator , to analyze future returns on Lifeline Biotechnologies.
Risk-Adjusted Performance
14 of 100
Weak | Strong |
Good
Compared to the overall equity markets, risk-adjusted returns on investments in Lifeline Biotechnologies are ranked lower than 14 (%) of all global equities and portfolios over the last 90 days. In spite of very conflicting fundamental drivers, Lifeline Biotechnologies displayed solid returns over the last few months and may actually be approaching a breakup point. ...more
Lifeline |
Lifeline Biotechnologies Relative Risk vs. Return Landscape
If you would invest 0.06 in Lifeline Biotechnologies on October 10, 2024 and sell it today you would lose (0.04) from holding Lifeline Biotechnologies or give up 66.67% of portfolio value over 90 days. Lifeline Biotechnologies is currently generating 12.6651% in daily expected returns and assumes 67.4417% risk (volatility on return distribution) over the 90 days horizon. In different words, most equities are less risky than Lifeline, and most traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Lifeline Biotechnologies Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Lifeline Biotechnologies' investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as Lifeline Biotechnologies, and traders can use it to determine the average amount a Lifeline Biotechnologies' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1878
| Best Portfolio | Best Equity | LLBO | ||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 67.44 actual daily | 96 96% of assets are less volatile |
Expected Return
| 5.01 actual daily | 96 96% of assets have lower returns |
Risk-Adjusted Return
| 0.19 actual daily | 14 86% of assets perform better |
Based on monthly moving average Lifeline Biotechnologies is performing at about 14% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Lifeline Biotechnologies by adding it to a well-diversified portfolio.
Lifeline Biotechnologies Fundamentals Growth
Lifeline Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Lifeline Biotechnologies, and Lifeline Biotechnologies fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Lifeline Pink Sheet performance.
| Current Valuation | 4.25 M | |||
| Cash And Equivalents | 603.32 K | |||
| Total Debt | 448.07 K | |||
| Debt To Equity | 0.08 % | |||
| Book Value Per Share | 0 X | |||
| Total Asset | 6.72 M | |||
About Lifeline Biotechnologies Performance
By examining Lifeline Biotechnologies' fundamental ratios, stakeholders can obtain critical insights into Lifeline Biotechnologies' financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Lifeline Biotechnologies is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
Lifeline Biotechnologies, Inc. operates as a medical technology company in the United States. Lifeline Biotechnologies, Inc. is headquartered in Reno, Nevada. Lifeline Biotech operates under Medical Devices classification in the United States and is traded on OTC Exchange.Things to note about Lifeline Biotechnologies performance evaluation
Checking the ongoing alerts about Lifeline Biotechnologies for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Lifeline Biotechnologies help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Lifeline Biotechnologies is way too risky over 90 days horizon | |
| Lifeline Biotechnologies has some characteristics of a very speculative penny stock | |
| Lifeline Biotechnologies appears to be risky and price may revert if volatility continues | |
| Net Loss for the year was (574.27 K) with profit before overhead, payroll, taxes, and interest of 0. |
- Analyzing Lifeline Biotechnologies' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Lifeline Biotechnologies' stock is overvalued or undervalued compared to its peers.
- Examining Lifeline Biotechnologies' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Lifeline Biotechnologies' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Lifeline Biotechnologies' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Lifeline Biotechnologies' pink sheet. These opinions can provide insight into Lifeline Biotechnologies' potential for growth and whether the stock is currently undervalued or overvalued.
Other Information on Investing in Lifeline Pink Sheet
Lifeline Biotechnologies financial ratios help investors to determine whether Lifeline Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Lifeline with respect to the benefits of owning Lifeline Biotechnologies security.